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Understanding immune tolerance mechanisms is a major goal of immunology research, but 
mechanistic studies have generally required the use of mouse models carrying untargeted or 
targeted antigen receptor transgenes, which distort lymphocyte development and therefore 
preclude analysis of a truly normal immune system. Here we demonstrate an advance in in 
vivo analysis of immune tolerance that overcomes these shortcomings. We show that custom 
superantigens generated by single chain antibody technology permit the study of tolerance 
in a normal, polyclonal immune system. In the present study we generated a membrane-
tethered anti-Ig
 

 
–reactive single chain antibody chimeric gene and expressed it as a transgene 
in mice. B cell tolerance was directly characterized in the transgenic mice and in radiation 
bone marrow chimeras in which ligand-bearing mice served as recipients of nontransgenic 
cells. We find that the ubiquitously expressed, Ig
 

 
-reactive ligand induces efficient B cell 
tolerance primarily or exclusively by receptor editing. We also demonstrate the unique 
advantages of our model in the genetic and cellular analysis of immune tolerance.
 
Immunological tolerance is important in pre-
venting autoimmunity and in promoting the
efficiency of immune responses. Tolerance has
been assessed experimentally in two general
ways. First, tolerance in normal polyclonal in-
dividuals has been measured by evaluating re-
sponses revealed by subsequent immunization
in vivo or in vitro (for review see references 1,
2). This first approach has the advantage of ad-
dressing a normal immune system, but because
of the extreme heterogeneity of lymphocyte
specificity and the low precursor frequency of
antigen-specific lymphocytes, it makes analysis
of tolerance mechanisms difficult or impossible.
A second approach has involved the use of anti-
gen receptor transgenic mice, which artificially
increase the frequency of antigen-reactive cells
by limiting or fixing expression of one or both
receptor chains, permitting the visualization of
cells with fully or partly defined specificities
(3–6). Antigen receptor transgenics have become
indispensable reagents in the study of lympho-
cyte biology, allowing analysis of development,
selection, specificity, and memory. But trans-
genic models are designed to distort lymphocyte
development, subverting the “allelic exclusion”
mechanisms to generate quasi-monoclonal im-
mune systems in defined lymphocyte subsets.
Furthermore, antibody transgenics, or the more
recent approach of targeted transgenics, have a
number of inherent drawbacks, owing to non-
physiological changes, such as accelerated B
cell development, a tendency to skewing in B
cell subset, and nonphysiological D
 
H
 
-to-VDJ
 
H
 
joining (7–10). Therefore, a variety of experi-
mental conclusions based on the use of antigen
receptor transgenic mice, in particular the rela-
tive contributions of different tolerance mech-
anisms to central and peripheral immune toler-
ance, require verification in normal, polyclonal
immune systems.
One mechanism by which tolerance can
occur in B cells is receptor editing, in which
self-reactivity directly or indirectly induces on-
going recombinase activator gene (RAG) ex-
pression and secondary Ig light chain rear-
rangements that alter receptor specificity (6,
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11–13). Receptor editing may be a major self-tolerance
mechanism in immature B cells (14–20). Many studies indi-
cate that the precursor frequency of autoreactive B cells is
high and that autoreactivity may be corrected by light chain
exchange (11, 12, 14, 21–26). Recent studies by Warde-
mann et al. show that reverse genetic analysis of human B
cell antibody expression can be a fruitful approach to study
repertoire and tolerance (23, 26). However, to date, studies
demonstrating in vivo receptor editing have primarily relied
upon analysis of receptor gene transgenic mice, the limita-
tions of which have been discussed.
On the other hand, immune responses can sometimes
also be analyzed in polyclonal models of the immune system,
and with appropriate experimental tools this analysis can
provide additional advantages over receptor gene transgenics
because lymphocyte development is not radically altered.
For example, lymphocyte responses can be modeled by stim-
ulation with anti-Ig and anti-TCR reagents (27–34), or
through the use of TCR
 

 
-reactive superantigens, which
among other things provided early evidence for clonal dele-
tion and T cell anergy in lymphocytes (35, 36). B cell–reac-
tive superantigens also exist, notably HIV gp120, 
 
Staphylococ-
cal
 
 toxin protein A, and 
 
Peptostreptococcus
 
 protein L (37–39).
The premise of this study is that custom superantigens,
generated by single chain Fv antibody engineering technol-
ogy, can be expressed as transgenes to regulate or tolerize a
fully normal, polyclonal immune system. To test this idea, we
generated mice expressing a single chain antibody combining
site reactive to the constant portion of mouse Ig
 

 
 L chain,
which was engineered to be expressed as a membrane pro-
tein. We then used these mice to assess the mechanisms of B
cell tolerance in vivo in a polyclonal immune system. This
approach provides the advantages of a ligand that reacts iden-
tically with the antigen receptors of a high frequency of pre-
cursor cells, but does so without prior skewing of lymphocyte
repertoire or subset, and in fact can be used with entirely nor-
mal cells. We call our synthetic superantigens “macroself” an-
tigens to distinguish them from natural superantigens. We
show here that a ubiquitously expressed Ig
 

 
-macroself anti-
gen can promote central tolerance and receptor editing in a
polyclonal immune system in vivo. Furthermore, we show
that transgenic mice expressing 
 

 
-macroself antigen can facil-
itate the analysis of mutations that affect tolerance processes.
 
RESULTS
Generation of 
 

 
-macroself antigen constructs and 
transgenic mice
 
To express an Ig
 

 
-specific macroself antigen of the predicted
structure indicated schematically in Fig. 1 A, we assembled
the gene construct depicted in Fig. 1 B. The antigenic speci-
ficity was generated by forming a single chain Fv from the
variable genes of a rat anti–mouse C
 

 
 hybridoma. We also
chose to include hinge regions and Fc portion from rat IgG1
to promote protein stability, bivalency, and flexibility, and to
project the binding sites away from the plasma membrane.
The transmembrane and intracytoplasmic regions of the pro-
tein were derived from the H-2K
 
b
 
 gene, which we assumed
were compatible with ubiquitous cell surface expression. A
construct carrying the chimeric gene driven by a human cy-
tomegalovirus promoter was transfected into L cells and sta-
ble clones were selected. Flow cytometry analysis revealed
that the transfectants expressed the predicted chimeric pro-
tein on the cell surface as they reacted with a monoclonal
antibody to the Fc portion of rat IgG1 (Fig. 1 C, left). Most
importantly, the transfectants bound a mouse IgG2b mono-
clonal antibody carrying 
 

 
 L chain, but not to a IgG2b/
 

 
 an-
tibody (Fig. 1 C, right), indicating that the synthetic gene
encoded a cell surface protein with the desired specificity for
mouse 
 

 
 chain.
To study the effect of a ubiquitously expressed 
 

 
-macro-
self antigen on B cells in vivo, transgenic mice were gener-
Figure 1. Design and in vitro testing of a synthetic B cell superan-
tigen. (A) Schematic representation of the predicted protein structure of 
membrane bound anti–mouse Ig-macroself Ag. A single chain Fv gener-
ated from the anti- hybridoma 187 is linked to the hinge and membrane 
proximal domains of rat IgG1 followed by transmembrane and cytoplasmic 
tail regions (Tm/Cy) of H-2Kb. (B) Gene construct encoding -macroself 
antigen showing intron/exon structure and selected features. Introns are 
depicted as thin lines. (G4S)3 refers to linker codons in one letter amino 
acid code: GGGGSGGGGSGGGGS. For stable transfection analysis, the 
gene shown was inserted into an expression vector providing a human 
cytomegalovirus promoter and zeocin resistance gene, generating plasmid 
pmSCA187CH1. (C) Flow cytometry analysis of stably transfected cell 
lines. Two clones were analyzed for surface expression of the macroself 
Ag. (Left) Staining with an anti–rat IgG1 monoclonal antibody compared 
with empty vector-transfected control. (Right) Testing of binding specific-
ity of the macroself antigen to mouse Ig light chain isotype. Two transfec-
tant cell lines were incubated with soluble mouse IgG2b, or IgG2b, and 
binding revealed with a secondary rat anti–mouse IgG2a/b reagent.
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ated using the construct shown in Fig. 2 A. A leader intron
was included in this construct because it improved expres-
sion in transient transfection by 
 

 
10-fold (unpublished data)
and the ubiquitin C promoter was chosen because it pro-
vided a more uniform and ubiquitous expression than a
mouse MHC class I H-2K
 
b
 
 promoter tested (unpublished
data). To avoid potential toxicity caused by maternal Ig
 

 
 an-
tibodies, microinjected zygotes were implanted in foster
mothers that were Ig
 

 
 deficient (40). Several transgenic lines
were generated, four of which were selected for further
study. As shown in Fig. 2 B, all lines expressed macroself an-
tigen on virtually all tested cells: lines #2, #37, and #20 ex-
pressed at relatively high, uniform levels in lymphoid tissues,
whereas line #26 was expressed more weakly, particularly in
bone marrow.
Flow cytometry analyses were performed to determine if
the 
 

 
-macroself antigen influenced the development of
 

 
-expressing B cells and to see if there was an effect on 
 

 

 
 
 
B
cells. All four transgenic lines had a similar, striking phenotype:
in the 
 

 
-macroself transgenic mice, virtually all of the B220
 

 
cells expressed 
 

 
 L chains and failed to express 
 

 
 L chains (shown
in Fig. 3 for line #2 and #26 splenocytes, and summarized for
all lines in Fig. 4, D and E). As shown in the lower right panels
of Fig. 3, 
 

 
75% of B cells in the spleens of 
 

 
-macroself antigen
mice were stained with a monoclonal antibody to 
 

 
1–3. The
remaining cells likely expressed V
 

 
x because these cells ex-
pressed sIgM, but failed to react to anti-
 

 
 or anti-
 

 
1–3
 
 anti-
bodies; moreover, 
 

 
-deficient mice (
 

 

 
/
 

 
) had a similar
population of IgM
 

 
,
 

 
1–3
 

 
 cells (Fig. 3). Similar losses of 
 

 

 
cells and increases in 
 

 

 
 cells were observed in lymph nodes of
the transgenic mice (Fig. 4, D and E). Peripheral B cell num-
bers were reduced 
 

 
50% in all 
 

 
-macroself antigen transgenic
lines (total splenic cells and the B220
 

 
 fraction were reduced
to, respectively, 80 and 60% of control levels; Fig. 4, A and C);
in contrast, bone marrow B220
 

 
 cell numbers were un-
changed in transgenic mice (Fig. 4 C). The percentages of 
 

 

 
cells in peripheral lymphoid tissues of 
 

 
-macroself transgenic
mice were increased relative to nontransgenics by over seven-
fold (Fig. 4 E), representing an overall numerical increase of
three- to fourfold. These results indicate that in all 
 

 
-macroself
transgenic lines 
 

 

 
 cells were absent from the peripheral lym-
phoid organs and 
 

 

 
 cell numbers were substantially increased.
Flow cytometry was also used to look for differences be-
tween normal and 
 

 
-macroself antigen-expressing mice in
peripheral B cell subsets (Fig. 4, F and G). The 
 

 
-macroself
antigen has the unique advantages of possessing comparable
reactivity to receptors carried by most B cells present in all
Figure 2. Generation of -macroself antigen transgenics and in 
vivo transgene expression. (A) Schematic representation of DNA construct 
used for microinjection to generate transgenic mice. Elements shown are 
approximately to scale. The pUli construct is a derivative of the gene 
shown in Fig. 1 B. It contains the -macroself Ag under the control of the 
human ubiquitin C promoter. The construct contains a Ig light chain gene 
leader exon and first intron. (B) Flow cytometry analysis of -macroself 
antigen expression in bone marrow, spleen, and lymph nodes of pUli 
transgenic mice as detected using an anti–rat IgG1Fc antibody (dotted 
lines, nontransgenic cells; solid line, pUli transgenic cells). Results from 
four different pUli transgenic lines are shown.
Figure 3. Flow cytometry analysis of -macroself transgenic lym-
phoid tissues showing reduction in frequency of 1 B cells and increases 
in 1 B cells. Cells from the indicated organs of 8-wk-old normal litter-
mate, /, and transgenic lines #2 and #26 were analyzed. Lymphocytes 
were gated on forward scatter versus side scatter to eliminate myeloid 
cells, dead cells, and cell debris from the analysis (lymphocyte gate). The 
results shown are representative of at least four experiments. (Top) Analysis of 
expression of B220 and Ig. Middle row of panels, costaining for Ig13 
and Ig. (Bottom) B220 gated cells were analyzed for expression of IgM 
and Ig13. The percentage in each quadrant, rounded to the nearest 1% 
is indicated in the upper right corner of each plot.
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target populations. Among B220
 

 
 splenic cells there ap-
peared to be similar or somewhat increased percentages of
newly formed splenic B cells in 
 

 
-macroself transgenic lines
compared with littermate controls, whereas the percentages
of mature, follicular B cells were somewhat reduced and
those of marginal zone B cells increased (Fig. 4 F). Taking
into account the reduction of B220
 

 
 cells in the 
 

 
-macroself
antigen-expressing mice, we estimate that marginal zone B
cell numbers were not significantly reduced in the 
 

 
-macro-
self antigen transgenic mice, whereas follicular and newly
formed B cells were reduced by 
 

 
50 and 20%, respectively.
Peritoneal B-1 cells in the 
 

 
-macroself antigen transgenic
mice were similar in number to control littermates, but, like
other peripheral B cells in these mice, expressed 
 

 
, rather
than 
 

 
 L chains (Fig. 4 G). Consistent with these observa-
tions, analysis of serum IgM and IgG2a/b revealed a loss of
Ig
 

 
 and an increase in 
 

 
-carrying Igs in 
 

 
-macroself trans-
genic mice (Table I). Thus, the immune system appears to
readily adapt to the presence of an autoantigen reactive to
94% of normal B cell receptors.
 
Analysis of receptor editing
To determine if the increase in  B cells in -macroself an-
tigen-expressing mice was the result of receptor editing,
rather than proliferation of preexisting  cells, we first
quantitated in the bone marrow the frequency of newly
formed, B220intermediate/ cells, a measurement that has been
used as an indicator of the rate of new B cell production
(41). As shown in Fig. 5,  B cell production is increased
three- to fourfold in -macroself antigen-expressing mice
compared with nontransgenic littermates. This increase was
comparable to the increase seen in / mice, in which
bone marrow output of  cells is known to be elevated
(41). To independently measure the rate of new  B cell
production, we quantitated Ig gene excision products (Fig.
6, A and C). These episomal DNAs generated by gene as-
sembly fail to replicate upon cell division, and hence are a
sensitive indicator of receptor editing (11). As shown in Fig.
6 C, the levels of V-to-J excision products were ele-
vated approximately threefold in isolated B220 bone mar-
row cells of -macroself antigen-expressing mice, relative to
littermate controls, consistent with the estimated increased
bone marrow output of  cells. An even greater increase in
the relative levels of  excision product was seen in splenic
B220 cells of transgenic mice (Fig. 6 C), suggesting that
most splenic cells had undergone little or no proliferation
since their generation. Once again, -macroself antigen-
expressing mice revealed a phenotype similar to / mice.
We conclude that -macroself transgenic mice have an in-
creased rate of  gene rearrangement and  B cell produc-
tion in the bone marrow.
Independent indices of receptor editing were measured to
verify the additional predictions that recombinase expression
and destructive Ig rearrangements should be increased in
-macroself transgenic mice. RAG1 and RAG2 mRNA ex-
pression levels in -macroself transgenic bone marrow B220
Figure 4. Elimination of Ig B cell and increase of Ig cell number 
in -macroself transgenic mice. (A–G) Histograms show mean of total 
cell numbers (A) and the percentages (SEM) of (B) IgM, (C) B220, (D) 
Ig and (E) Ig in bone marrow, spleen, and lymph nodes of the indicated 
mouse genetic types. All data except A and G involved use of a lymphocyte 
gate. (F) Mean percentages of immature, mature, and marginal zone 
splenic B cells. (G) Shown are mean percentages of Ig and Ig B lym-
phocytes in the peritoneal cavity, gated on large, CD5 lymphocytes to 
focus on the B-1 subset. These cells were B220intermediate, IgMhigh, and IgDlow. 
In the inset the number of experimental animals analyzed per group is 
noted in parentheses next to the symbol of mouse type.
Table I. Serum immunoglobulins of unimmunized -macroself transgenic mice
Mouse strain (n) Total IgM IgM,  IgM,  IgG2a/b,  IgG2a/b,  
g/ml  g/ml units/ml g/ml g/ml
Nontransgenic (4) 113  78 75  21 6  4 211.0  91.0 0.6  0.1
/ (4) 163  60 	 0.6 79  39 0.6  0.1 42.0   8.0
Transgenic #2 (4) 188  81 	 0.6 76  33 0.7  0.2 101.0  29.0
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cells were significantly elevated by 80 to 90% over nontrans-
genic controls (Fig. 6 B). Recombining sequence (RS; 42,
43) recombination to the acceptor sites in the J-C intron
was also evaluated as a measure of destructive V(D)J recombi-
nation on the  locus of B cells (Fig. 6 A). RS, which is
found 25-kb downstream of the C exon, undergoes
RAG-mediated recombination to Vs and to two acceptor
sites in the J-C intron (IRS1 and IRS2) that inactivate the 
locus (44). RS recombinations are common in  cells and
are also seen in 10% of normal  cells (16, 45, 46). RS re-
combination to IRS1 and IRS2 was elevated in bone marrow
and spleens of -macroself transgenic mice (Fig. 6 A, RS to 
intron rows). Taken together with data showing similar in-
creases in RAG expression and  B cell production in -defi-
cient and -macroself transgenic mice, the data suggested that
-macroself antigen induces efficient central B cell tolerance
in an otherwise normal immune system by a mechanism of
developmental arrest and receptor editing.
Analysis of bone marrow B cell turnover and intracellular 
Ig expression
To further quantitate the relative roles of receptor editing and
clonal deletion in the tolerance induced by -macroself anti-
gen, the intracellular Ig expression and BrdU uptake of
newly formed bone marrow B cells was assessed. Despite the
data indicating excess RAG expression, RS recombination
and  gene excision product DNA in the bone marrow of
-macroself mice, it remained possible that clonal deletion de-
pleted developing  cells, allowing excess survival and a non-
proliferative buildup of  cells. Such a hypothesis predicts an
increased turnover of B cells in -macroself bone marrow and
a drastic reduction of developing B cells carrying  chains,
whereas editing should not increase B cell turnover. Turnover
was assessed by daily injection of BrdU and assessment of up-
take in bone marrow B cells over time (47). As shown in Fig.
7 A (left), BrdU uptake in the B220intermediate bone marrow B
cell population was similar or slightly slower in -macroself
transgenic mice, compared with wild-type littermates, indicat-
ing that the -macroself antigen does not accelerate bone
marrow B cell turnover. BrdU uptake was delayed in the
sIgM fraction of newly formed -macroself transgenic B cells
compared with wild type, suggesting a longer average transit
time (Fig. 7 A, right). These results were further supported by
intracellular immunoglobulin staining experiments as -mac-
roself antigen mice had significant numbers of intracellular 
B cells in bone marrow, but not in the spleen (Fig. 7 B, lower
rows). The frequency of cytoplasmic Ig cells was only mar-
ginally reduced (by 13%) among the newly formed,
B220intermediate B cells in the presence of -macroself antigen
(Fig. 7 D). Moreover, cytoplasmic  cells costained with an
IgM antibody (Fig. 7 C). Because both the anti- and anti-
IgM antibodies used see only assembled immunoglobulins (48,
Figure 5. Increased output of Ig cells in -macroself antigen 
mice. (A) Bone marrow cells from /, -macroself transgenic, or non-
transgenic littermate mice were stained with B220 and Ig13 and ana-
lyzed by flow cytometry. The B220intermediate/ population is found in the 
lower box. Data shown was analyzed using a lymphocyte gate. (B) Summary 
of quantitation of newly formed  cells as illustrated in A. Newly formed 
 cell numbers (obtained from the bone marrow of two legs) were 0.3 
(0.1), 0.7 (0.2), and 1 (0.3) million cells in the nontransgenic litter-
mate, the / and the -macroself transgenic mice, respectively.
Figure 6. Evaluation of molecular parameters of receptor editing 
in -macroself transgenic, littermate control, and / mice. 
(A, top rows) PCR detection of V1–J1 rearrangement excision products 
in genomic DNA extracted from anti-B220 magnetic bead purified B cells 
of bone marrow and spleen. Fourfold DNA serial template dilutions were 
tested. Tail DNA was used as a negative control (lane 17). PCR products 
were quantitated by Southern blot using specific probes. (Middle rows) 
Detection of RS-to-IRS1 and RS-to-IRS2 joins. (Bottom rows) PCR product 
located 3
 to the 3
-RS Ig sequence is used as a DNA loading control 
(control). (B) Quantitation of RAG1 and RAG2 mRNA levels in B220 bone 
marrow cells by quantitative Northern blot. (C) Quantitation of Ig V1-to-J1 
excision product rearrangements detected by PCR in DNA of B220 cells 
isolated from bone marrow or spleens of the indicated mouse types.
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49), we infer that the bone marrow B cells of -macroself an-
tigen mice that carry sIg undergo receptor down modulation
followed by receptor editing.
Transplantation of mutant bone marrow in -macroself 
antigen-expressing hosts
Because the -macroself transgenics express antigen on all
cells tested, including B cells, we assessed B cell tolerance in
radiation bone marrow chimeras in which -macroself trans-
genic line #2 mice served as hosts and donor bone marrow
cells lacked macroself transgenes (Fig. 8 and Table II). Three
types of bone marrow donors were used in these experi-
ments: nonmutant controls (wt), mice carrying a hemizy-
gous deficiency in the RAG1 gene (RAG/; 50), and mice
carrying a Bcl2 transgene expressed in the B cell compart-
ment (51). Use of wild-type donors assessed the ability of
-macroself antigen to promote tolerance in a population of
cells that was completely normal and lacking in any genetic
Figure 7. Intracellular immunofluorescence analysis of BrdU uptake 
and immunoglobulin expression in -macroself transgenic mice and 
littermates. (A) BrdU uptake with time of labeling in bone marrow 
B220intermediate cells of transgenic mice (open circles) or littermates (dia-
monds). (Left) BrdU incorporation in total B220intermediate cells; (right) BrdU 
incorporation in sIgM/B220intermediate cells. (B) Comparison of surface Ig 
staining (top), with intracellular Ig staining (bottom). (C) Costaining for in-
tracellular Ig and either sIgM alone (left) or both surface and cytoplasmic 
IgM (right). (D) Statistical analysis of experiments shown in b and c. Left pair 
of bars shows the percentages of cells found in lower analysis boxes of 
B220/intracellular Ig stain (i.e., B, bottom). The right pair of bars shows 
percentages of cells in upper two quadrants of intracellular IgM/intracellu-
lar Ig stain with B220low gate (C, right). Means and standard deviations are 
indicated. Filled bars, transgenic; open bars, nontransgenic littermates.
Figure 8. Flow cytometry analysis of tolerance induction in radia-
tion chimeras using -macroself transgenic hosts. Mice were ana-
lyzed at 6 wk post reconstitution. (A and B) Analysis of bone marrow 
lymphocytes using anti-L chain and B220 antibodies. Bone marrow donors 
are indicated to the left of the arrows, the recipient mouse genotypes are 
shown just below. Newly formed lymphocytes carrying Ig- or -, were 
identified as falling in the lower analysis boxes, as indicated. (A) B6 (wt) or 
RAG/ bone marrow was used to reconstitute lethally irradiated CD45.1/
-macroself transgenic #2 (Tg #2) or littermate recipients. (B) Comparison 
of chimeras generated with bone marrow from Bcl-2 transgenic or litter-
mate (wt) donors, using as irradiated recipients either transgenic #2 or 
littermate. (C) Analysis of spleen cells from the indicated radiation chimeras. 
Recipient mouse genotype is shown to the right of arrows above dot plots. 
Cells were stained with B220 and anti- antibodies (top) or anti- and 
anti- antibodies (bottom).
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modifications. The results observed in line #2 hosts carrying
wild-type donor cells were generally similar to those ob-
tained in unmanipulated line #2 mice, except that cells in
the bone marrow carrying low levels of Ig were more ap-
parent (Fig. 8 A, compare lower left pair of panels). Splenic
B cells in transgenic #2 recipients were largely devoid of 
expression, but instead expressed  chains (Fig. 8 C, right
panels under “wt”). In addition, transgenic #2 recipients
manifested an increased frequency of B220intermediate,  cells
in the bone marrow (Fig. 8 A). Thus, nontransgenic B cells
developing in -macroself line #2 appeared to undergo cen-
tral tolerance and receptor editing.
The RAG/ mutant and Bcl2 transgenic donors were
tested to determine the feasibility of using -macroself trans-
genics to rapidly screen mouse mutant strains for defects in
immune tolerance. We reasoned that enforced Bcl2 expres-
sion should suppress apoptosis, whereas heterozygous defi-
ciency in RAG1 might hinder receptor editing. Bone mar-
row chimeras carrying RAG/ or Bcl2 transgenic bone
marrow manifested subtle, but reproducible, differences
from chimeras reconstituted with wild-type bone marrow
(shown in bold in Table II). Chimeras reconstituted with
Bcl2 transgenic marrow had elevated frequencies of  cells
in the absence of -macroself antigen, and an even further
enhanced  frequency in -macroself recipients (Fig. 8 C);
furthermore, these increases were paralleled by a rise in
newly formed B220intermediate/ cells in the bone marrow
(Fig. 8 B). We conclude that the survival-enhancing effects
of enforced Bcl2 expression do not block central B cell tol-
erance to -macroself antigen, but instead promote increased
generation of  cells. This increase in , along with the fur-
ther-reduced frequency of  cells in the bone marrows of
-macroself recipients reconstituted with Bcl2 transgenic
cells, likely occurs because of an extended lifetime for edit-
ing. In contrast, chimeras reconstituted with RAG/ bone
marrow had a subnormal peripheral B cell frequency that
was exacerbated by the presence of -macroself antigen.
Furthermore, RAG/ cells had a significantly smaller
-macroself antigen-induced increase in the rate of  B cell
production relative to wild type (Fig. 8 A). An additional
anomaly observed in RAG/ chimeras was a relative reten-
tion in the bone marrow of -macroself antigen recipients of
cells carrying high levels of Ig (Fig. 8 A, lower right). Thus,
loss of surface Ig expression in bone marrow B220 cells of
-macroself antigen transgenic mice is partly related to edit-
ing and is not wholly a result of receptor protein down mod-
ulation. Similar results were obtained in RAG/ mice car-
rying the line #26 transgene (unpublished data). These
results suggest that reduced RAG1 gene dosage suppresses
or, more likely, slows tolerance-induced receptor editing,
reducing the  to  isotype switch in developing B cells.
This finding in turn may suggest that RAG1 levels are limit-
ing for receptor editing.
DISCUSSION
The -macroself antigen approach that we introduce here is
a strategy to study immunological tolerance in a large poly-
clonal cohort of cells. In the present study, we have used
these mice to study immune tolerance in an otherwise un-
manipulated immune system. We were able to revisit the
Table II. Effect of Bcl2 overexpression and RAG1/ mutation in donor cells on receptor editing and tolerance induction in 
-macroself radiation chimeras
Percent positive 
mean  SD
Donor → Host (n)
Cells /106 
mean  SD B220 IgM   B220int B220int
Bone marrow
Wild type → wt (5) 68  6.6 78  13 15  2 21.0  2.0 2.7  0.5 12.8  2.0 1.7  0.1
→ Tg#2 (4) 50  13 74  9 8  3a 5.2  1.8a 4.9  1.4a 4.4  1.3a 2.7  0.3a
Bcl2 → wt (4) 56  13 84  5 35  2 33.0  7.0 8.6  1.2 22.5  3.0 9.3  0.6
→ Tg#2 (3) 61  17 74  8 22  2a 5.7  0.4a 15.0  2.5a 4.5  0.4a 15.0  3.0a
RAG1 → wt (4) 52  7 67  11 16  2 21.0  3.0 2.3  0.7 9.7  0.4 1.5  0.4
→ Tg#2 (3) 42  2 60  10 6  2a 8.3  2.0a 2.5  0.7 7.4  0.5a 1.3  0.2
Spleen
Wild type → wt (5) 67  23 66  3 50  2 5.0  6.0 4.0  1.0
→ Tg#2 (4) 43  7a 36  7a 28  5a 0.6  0.3a 27.0  7.0a
Bcl2 → wt (4) 146  33 84  3 63  14 65.0  8.0 10.0  2.0
→ Tg#2 (3) 83  20a 73  15 49  10 1.0  0.6a 41.0  5.0a
RAG1 → wt (4) 64  6 68  4 50  3 61.0  4.0 4.7  0.5
→ Tg#2 (3) 39  18a 29  6a 26  3a 0.2  0.1a 19.0  7.0a
Bone marrow sample data shows total cell counts, but percentages of B cell subsets are based on a lymphocyte gate. B220int refers to cells with intermediate levels of B220 and 
the indicated Ig light chain. 
aItems marked represent significant (P 	 0.05) differences between cells maturing in transgenic #2 compared to wild-type littermate hosts. Items in bold represent significant 
(P 	 0.05) differences associated with the mutant donor type, compared to wild-type donor type in the comparable host.
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question of whether or not B cell tolerance to a ubiquitous,
membrane-tethered self antigen occurs by receptor editing
or deletion (or if it occurs at all in normal cells). Importantly,
our approach allowed us to assess the relative contributions
of editing and deletion in a normal immune system. The
data indicate that both cell death and receptor editing con-
tribute to tolerance because substantial increases in  light
chain gene recombination and new  B cell production oc-
cur in -macroself antigen mice, but their overall B cell
numbers are reduced to 50%. It is known that  loci al-
most always recombine after  loci (45, 52), typically 24 h
later (53, 54). However, we believe that apoptosis induced
rapidly by autoreactivity (clonal deletion) appears to play a
minimal role in our model, whereas the cellular time limit
for editing to eliminate an autoreactive receptor exerts a
more severe restriction. Because 94% of B cells in non-
transgenic mice express , the reduction in B cell numbers is
less than predicted if generated  B cells are rapidly elimi-
nated by cell death and not replaced by other cells. Indeed, B
cells in -macroself transgenic mice resembled those of /
mice, which cannot be subject to negative selection of sIg
(Fig. 3). Tolerance purely by rapid clonal deletion of devel-
oping B cells would be predicted to reduce  B cell output
while leaving  B cell generation unchanged. Results of
BrdU uptake studies and Ig cytoplasmic staining were in-
compatible with significant rapid clonal deletion. Indeed, in
the presence of -macroself antigen the turnover of imma-
ture B cells was actually slowed, while the fraction of newly
formed  cells increased substantially. Rather, the results
are most easily explained by a tolerance-induced develop-
mental arrest, followed by significant, but incomplete, rescue
by editing.
If editing occurs by developmental arrest without in-
duced deletion in -macroself transgenic mice these trans-
genics should resemble / mice. This is in fact the case:
their percentages of B cells in various lymphoid compart-
ments are quite similar. We have assessed mice carrying
-macroself antigen on a background in which one of the 
constant alleles carried the human sequence (17) and found
minimal B cell attrition compared with wild type (unpub-
lished data). This would be consistent with findings indicat-
ing that the efficiency of rescue of autoreactive cells by edit-
ing is visibly affected only by severely reducing the number
of L chain genes available for editing, such as by knocking
out the  locus, or limiting the available repertoire of Js
(20, 25, 55–57). In contrast to these studies, however, our
present results were obtained in a context in which B cell
development was unaltered.
Anti-Ig suppression of B cell development in vivo and in
vitro has been studied for many years (27–32, 34, 58–60).
Work first done in chickens, then later in mice and rats,
showing that antibodies introduced into developing embryos
suppressed B cell development represented the first evidence
for clonal abortion (for review see reference 61). In some
studies, evidence of developmental arrest was seen, including
“irreversible” receptor down-regulation (28, 59). Typically,
mature B cells were absent from the periphery while B cell
progenitors were retained in the bone marrow. However, in
other studies, anergy was induced, rather than deletion (30,
32). Often, competitive advantage was had by B cells that
did not react with antibody (31, 58, and for review see refer-
ence 61). Our results are similar in several ways to a study of
anti- suppressed mice by Weiss et al., in which the loss of
 B cells and  immunoglobulin in serum was compen-
sated for by an increase of peripheral  B cells and serum
immunoglobulin  (31). In any case, the prior studies were
often consistent with our conclusions in that the immature B
cells receiving anti-Ig constant region stimulus did not die
immediately, though none of these studies proposed an edit-
ing type escape mechanism.
Our ability to probe immune tolerance using macroself
transgenic mice as adoptive hosts for normal or mutant bone
marrow is important for several reasons. First, it establishes
that the macroself antigen need not be expressed by B cells
to induce tolerance in wild-type B cells. Second, we estab-
lish that wild-type B cells are tolerance susceptible by editing
in vivo, a finding that to our knowledge has never before
been directly demonstrated in a non-Ig transgenic mouse.
Third, we demonstrate that macroself transgenic mice allow
one to screen mutant bone marrow for defects in immuno-
logical tolerance. We confirmed earlier results, obtained in
3–83 antibody transgenic mice carrying autoreactive recep-
tors, indicating that enforced B cell expression of Bcl2 facili-
tated receptor editing, but did not rescue autoreactive B cells
from central tolerance (62). This last is consistent with the
notion that the incomplete editing to  in -macroself anti-
gen transgenic mice is limited by the life span of editing
competent cells, which can be artificially prolonged by en-
forced Bcl2 expression. In other words, we believe that au-
toreactive cells arrested in development and undergoing light
chain rearrangements are subject to death by neglect, which
can be slowed by Bcl2. Furthermore, we have made the
novel additional finding that reducing RAG1 gene dosage
impairs B cell production and receptor editing. (This result
was independently confirmed using conventional Ig trans-
genic mice; unpublished data).
Although antigen receptor transgenic mice are a valuable
resource for many studies, by design they perturb lympho-
cyte development, resulting in a number of anomalies. For
example, targeted or randomly integrated transgenes are typ-
ically prematurely expressed, and are generally in an unusual
antigen receptor gene context, such as in conventional IgH
transgenics, which cannot undergo H chain class switch, or
in targeted VDJh transgenics, where the introduced gene is
downstream of germline D elements and can be eliminated
by DJ joining. Furthermore, antigen receptor transgenes
usually skew lymphocyte subset distributions, such as CD4/
CD8 ratios in T cells or B-1/follicular ratios in B cells. Mac-
roself antigen mice overcome many of these drawbacks. Im-
portantly, the macroself approach can, in theory, be easily
used for any antigen receptor for which there is a monoclo-
nal antibody.
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We note that B cells have the striking propensity to alter
their Ig constant region usage during development, a feature
that makes their analysis by challenge with macroself Ags po-
tentially fruitful. Early in development, when bone marrow
B cells express exclusively sIgM, receptor editing can cause
successive Ig- allele usage, and can lead to a progression
from usage of  to  L chain. Later in development, B cells
up-regulate sIgD, marking the beginning of a phase that in-
cludes migration to the spleen and final preimmune matura-
tion. After encounter with antigen, reactive B cells often un-
dergo a heavy chain class switch, leading to the loss of IgM
and IgD, and their replacement by downstream H chain C
regions. Hence, macroself Ags reactive to Ig-, IgD, and
IgG C-regions would be expected to promote immune tol-
erance in a polyclonal immune system at different develop-
mental stages, and quite possibly by different mechanisms. As
macroself antigens with specificity to other antigen recep-
tors, such as TCRs, can be easily generated, they may pro-
vide useful tools for studies in other cell types. Future studies
will focus on such possibilities.
With the advent of germline mouse knockout technol-
ogy, autoimmune-prone congenic strains, and genome-wide
ethylnitrosourea mutagenesis studies, there is an increasing
need to devise methods to rapidly screen mutant mice for im-
mune tolerance phenotypes. At the present time, this is typi-
cally approached by crossing of the knockout in question to
antigen receptor transgenic mice and then introducing the
cognate (auto)antigen. Because it requires a minimum of two
generations of breeding, and extensive mouse genotyping,
this approach is time consuming and expensive, and therefore
not ideal for the screening of large numbers of mutants. Gen-
eration of well-conceived macroself Ag mice could provide a
means to greatly speed up this screening process. Our results
show that mutant mouse bone marrow or fetal liver precursor
cells could be used to reconstitute lethally irradiated macroself
Ag-expressing mice, and the development and function of
the transferred cells could be directly monitored. Because the
macroself Ag mice carry specific ligands that react with a sub-
set of normal lymphocytes, no special breeding is required,
particularly if the macroself Ag transgene is maintained on the
same genetic background. Macroself Ag transgenic mice with
specificity for defined lymphocyte receptor elements can fa-
cilitate the analysis of mouse mutants, particularly those with
known signaling defects.
MATERIALS AND METHODS
Generation of -macroself gene constructs. RNA was isolated from
the rat anti- hybridoma 187(49) (American Type Culture Collection), and
expressed antibody genes were cloned by 5
 rapid amplification and cloning
of ends (5
-RACE) using the RLM-RACE PCR kit (Ambion) according
to the manufacturer’s instructions. The variable genes were amplified using
sense primer specific to the 5
 adaptor either with a rat C-specific anti-
sense primer (5
-CTAACTGTTCCGTGGATGGTGGG) to amplify the
light chain variable region, or a rat IgG1 anti-sense specific primer (5
-
GGCTCCAGAGTTCCAGGTCACGG) to amplify the heavy chain vari-
able region, together with their respective leader sequences. PCR products
were then cloned in a plasmid vector using the TOPO TA cloning kit (In-
vitrogen) and several clones sequenced to obtain consensus sequences and to
facilitate the identification of clones lacking mutations introduced by the
amplification and cloning. Independently, rat IgG1 H chain constant re-
gions were amplified from cDNA. To generate a single chain antibody gene
and linked elements a PCR sewing approach was taken using the following
oligonucleotide primers: primer 1 (5
VL) 5
-TCGCGAATCGCCGACA-
GGTGCGATGGACATGAGGGCCCATGCTC-3
; primer 2 (3
VL) 5
-
CCTCCCGAGCCACCGCCTCCGCTGCCTCCGCCTCCCCGTTT-
TATTTCCAACTTCGTCCCG-3
; primer 3 (5
VH) 5
-GCAGCGGAG-
GCGGTGGCTCGGGAGGCGGAGGCTCGCAGGTACAGCTGAAA-
GAGTCAGG-3
; primer 4 (3
VH) 5
-CCCGGGTTTCTGGGGGCTG-
TTGTTTCAGCTGAGGAGAC-5
; primer 5 (5
hinge) 5
-CAGAAACC-
CGGGAGGTGATTGCAAGCC; primer 6 (3
CH3) GGGAGTGGGAG-
AGACTCTTCTCAGTATGGTGG; 7 (5
Tm) 5
-GTCTCTCCCACTC-
CCCCGGTAAAGAGCCTCCTCCATCCAC; 8 (3
Tm) 5
-CCAACT-
TCACTCCAATGTCCCC. The “overlapping” sequences are underlined;
those recognized by restriction endonucleases are in italics. PCR products
corresponding to the LVJL and the VDJH region were initially amplified
with the primers 1 and 2, and 3 and 4, respectively. Rat C1 cDNA lacking
the CH1 domain (C1CH1) was amplified using primers 5 and 6. A seg-
ment of the genomic H-2Kb locus encoding the transmembrane (Tm) exon
5 was amplified using primers 7 and 8. The single chain Fv gene, including
the intervening flexible peptide codons (Gly4-Ser)3, was assembled by a sec-
ond PCR step with the outer primers 1 and 4, using as templates the LVL
and VH PCR products at a 1:1 molar ratio (total of 50 ng of DNA). Simi-
larly, the hinge, Fc, and Tm coding regions were assembled together by re-
combinant PCR with the primers 5 and 8 using as DNA templates PCR
products of primers 5  6 and 7  8. The Fv and the C1CH1 coding
regions were then successively cloned upstream of the genomic cytoplasmic
tail (exon 6–8) and the 3
 UTR of the H-2Kb gene in pBluescript II SK as
NruI/XmaI and XmaI/BglII restriction fragments, respectively. The result-
ing chimeric gene was then cloned downstream the cytomegalovirus gene
promoter (pCMV) as a NruI /EcoRI restriction fragment into the pBudCE4.1
expression vector (Invitrogen), generating plasmid pBudSCA187CH1,
which was used for transfection analysis. The construct used for the produc-
tion of transgenic mice (pUIik) was obtained as follows: the leader and the
first intron of the RF IgL chain (a gift from M. Shlomchik, Yale University,
New Haven, CT; reference 63) were added upstream of the 187.1 Fv by
recombinant PCR using the following primers: primer 9 (5
-leader) 5
-
TCGCGAATCGCCGACAGGTGCGATGGAATCACAGACCCAGG-
TCC; primer 10 (3
-intron) 5
-GGTCATCTGAATGTCTGCACAGGC-
ACCTGTAATAATTAATAGGC; primer 11 (5
-scFv) 5
-TACAGGTG-
CCTGTGCAGACATTCAGATGACCC; and primer 4 (see above). The
leader intron and the scFv 187.1 were first amplified by PCR using the
primers 9 and 10, and 11 and 4, respectively. The leader intron and the scFv
187.1 were fused together by recombinant PCR using the outer primers 9
and 4, and then cloned as a NruI/XmaI restriction fragment upstream of the
mC1CHI coding sequence. Finally, the 1.2-kb human ubiquitin C gene
promoter (64) was cloned upstream of the coding sequences as a HindIII/
NruI restriction fragment in pBluescript II SK.
Stable transfection of L929 cells. L929 cells were transfected with
pBudSCA187CH1 constructs using Lipofectamine/Plus reagent (Invitro-
gen) on six-well plates according the manufacturer’s recommendations. Sta-
ble transfectants were selected after 3 wk of growth in complete IMDM
medium containing 100 g/ml of Zeocin.
Mice. All mice were bred and maintained in the TSRI Animal Resources
facility according to The Scripps Research Institute Institutional Animal
Care and Use guidelines. C57BL6/J (B6), B6.RAG1/ (50) and
B6.CD45.1 mice were obtained from Jackson ImmunoResearch Laborato-
ries. Germline Ig J-C–deleted mice (40) were provided by D. Huzsar
(GenPharm Intl., San Jose, CA). EmuBcl-2-22 transgenic (Bcl2 Tg) mice
(51), were provided by Drs. Strasser and Harris (The Walter and Eliza Hall
Institute of Medical Research, Melbourne, Australia).
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Production of transgenic mice. The 4-kb pUli transgene construct
was separated from bacterial vector sequences by a digestion with HindIII/
EcoRI and agarose gel electrophoresis. The fragment was isolated and puri-
fied on Elutip-d columns (Schleicher & Schuell) according the manufac-
turer’s recommendations and dialyzed overnight against zygote injection
grade Tris-HCl-EDTA. Transgenic mice were produced by classical micro-
injection techniques at the TSRI Mouse Genetics Core Facility. (B6 x
DBA/2)F1 zygotes were microinjected with the pUli transgene and reim-
planted into the oviducts of pseudo pregnant / foster mothers. Mice an-
alyzed had been backcrossed three times to the B6.CD45.1 background.
Bone marrow chimeras. Recipient mice were -macroself transgenics
or littermate controls; all carried the CD45.1 allele. Recipients received 950
rads  radiation from a Cs source on the day of transfer. Bone marrow do-
nors were all of the CD45.2 allotype. Bone marrow cell suspensions were
depleted of T cells by treatment with biotinylated anti-Thy1.2 antibodies
and antibiotin magnetic beads (Miltenyi Biotec) according to the suggested
protocol. Five million cells were transferred i.v. per recipient. After 6 wk,
recipients were killed and their lymphoid tissues analyzed by flow cytome-
try. Only chimeras in which 98% of cells in bone marrow and spleen
were donor derived were included in the analysis.
Flow cytometry analysis. For the analysis of mouse cells ex vivo, nucle-
ated cell suspension were prepared from bone marrow, spleen, mesenteric
lymph nodes, and peritoneal cavity. Erythrocytes were eliminated from the
spleen and bone marrow preparations by ammonium chloride treatment.
Cells were stained in staining buffer containing appropriately diluted com-
binations of the following monoclonal antibodies: biotin-coupled mouse
anti–rat IgG1 (BD Biosciences) developed with streptavidin-PE; PE and bi-
otin rat anti–mouse Ig (187.1; BD Biosciences); biotin–anti-Ig1-3 (BD
Biosciences) followed by PE- or allophycocyanin-streptavidin; PerCP- or
FITC-coupled anti-CD45R/B220 (RA3-6B2; BD Biosciences); Cy5-cou-
pled anti-IgM (331.12), PE-coupled anti-CD45.1 (eBioscience); FITC-
coupled anti-CD45.2 (eBioscience). L929-transfected cells were harvested
using PBS, 0.5 mM EDTA, washed twice, and resuspended in staining
buffer (PBS, 1% BSA, 0.01% NaN3). Cells were incubated with biotin
mouse anti–rat IgG1 (BD Biosciences), which reacts with the linker region
of the macroself antigen, or mouse IgG2b monoclonal antibody carrying 
or  L chains, followed by biotin-coupled rat anti–mouse IgG2a (BD Bio-
sciences) to assess Fv binding site specificity. Biotin-coupled antibodies
were revealed with streptavidin-phycoerythrin (PE; BD Biosciences). Cells
were gated on the basis of forward and side scatter criteria to avoid contam-
ination by dead cells or debris. For intracellular staining and BrdU uptake
studies, surface stained cells were fixed and permeabilized using a kit (Cyto-
fix/Cytoperm™; BD Biosciences) and stained according to the manufac-
turer’s instructions. FITC anti-BrdU antibody was used (BD Biosciences).
Stained cells were analyzed on a FACSCaliber flow cytometer (Becton
Dickinson) using the FlowJo software package.
Excision product and RS-to-IRS PCR assays. B cells were isolated
from spleen and bone marrow using an anti-B220 magnetic bead cell purifi-
cation system (Miltenyi Biotec). The purity of these preparations was 90%
in all cases. Genomic DNA was extracted using the QIAamp DNA Mini
Kit (QIAGEN) according the manufacturer’s recommendations. PCR reac-
tion were done in a final volume of 50 l containing 100, 25, 12, and 6 ng
of B cell genomic DNA. V1-to-J1 excision product DNA rearrange-
ments were detected using the oligonucleotides and PCR conditions de-
scribed (11). RS-to-IRS PCR assay was performed using primers B and C
(16). Samples were amplified for 25 cycles: 1 min at 94C, 1 min at 60C,
and 1 min at 72C. PCR products were electrophoresed in 1.5% agarose
gels, blotted on nylon membranes, and probed with intervening sequence
probe as described previously (16).
Serum Ig determinations. Polyvinylchloride plastic microplates (Falcon)
were coated with a rat monoclonal antibodies specific for IgG2a,b (BD Bio-
sciences), IgM (331.12), or Ig1-3 (R26-46; BD Biosciences). After washing
and blocking, sera (diluted in PBS supplemented with 1% BSA) were incu-
bated 3 h at room temperature. Bound Ig was detected using biotinylated
anti–mouse Ig1-3, anti–mouse IgM (R6-60.2; BD Biosciences) or horse-
radish peroxidase–conjugated anti–mouse Ig (187.1; BD Biosciences).
Biotinylated antibodies were revealed using streptavidin-peroxidase (Sigma-
Aldrich) followed by addition of the chromogenic substrate 2,2
-azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich) in McIlvain’s
buffer (84 mM Na2PO4/48 mM citrate, pH 4.6). Absorbance was measured
on a Spectra MAX250 plate reader (Molecular Devices). Standard curves
were obtained using a mouse IgM, (G 155–228; BD Biosciences) and a
mouse IgM, (11E10; Southern Biotechnology Associates, Inc.) or a mouse
IgG2b, (BD Biosciences).
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